HIV 'rides' into cells on membrane rafts, NIAID scientists determine

November 19, 2001

The AIDS-causing virus, HIV, must attach to cholesterol-rich regions of a cell's membrane before it can do its destructive work, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have discovered. When the investigators removed cholesterol from the cells, HIV lost much of its ability to produce new virus particles and infect additional cells. These findings provide a more detailed picture of how HIV travels into and out of cells as well as possible ways to block that travel.

"Our research raises the intriguing possibility that widely used cholesterol-lowering drugs might have an effect in humans similar to what we have found in these initial laboratory studies," says Eric O. Freed, Ph.D., an investigator in NIAID's Laboratory of Molecular Microbiology, and the senior author of a paper published in the November 20 issue of Proceedings of the National Academy of Sciences.

HIV, like everything else passing into or out of an animal cell, must navigate the cell's complex double-walled outer membrane. Much like a bog, a cell membrane contains some areas of relatively solid material while other regions are more fluid. Among the features of this constantly shifting landscape are small, cholesterol-rich patches called rafts, which are more solid than the surrounding membrane and are able to move about like a raft on water.

Rafts are believed to be most concentrated at points of cell-to-cell contact in the immune cells that HIV targets for infection. Any mechanism that helps HIV find and attach to rafts would help the virus spread. Conversely, even a modest degree of disruption could slow the virus' spread because it would hinder the virus' ability to enter and leave its host cells.

Scientists have known for some time that an HIV protein called Gag must attach to the inner surface of the cell membrane before new viruses can be produced. Scientists also suspected that Gag's attachment to the membrane is not random, but rather targets specific regions of the cell surface. The new research shows their suspicions were correct.

Dr. Freed and his co-author Akira Ono, Ph.D., first established that Gag does indeed attach to rafts. They then created several mutant forms of Gag and learned that two pieces of the protein are required for successful attachment. Finally, the investigators turned to the key question of what happens when HIV is kept off the rafts.

To determine this, they depleted cholesterol from rafts using two compounds, one of which removes cholesterol rapidly from the cell surface and one that inhibits cholesterol synthesis. When used alone, each compound significantly reduced HIV's ability to form particles that could infect new cells. Applied simultaneously to virus-producing cells, the compounds almost completely abolished HIV's power to replicate.

"Our findings are clear evidence that Gag-raft association is a critical step in HIV replication," says Dr. Freed. "Additional experiments are needed to determine whether this interaction can be interrupted therapeutically to treat HIV-infected people."
-end-
NIAID is a component of the National Institutes of Health (NIH). NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

Reference: A Ono and EO Freed. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proceedings of the National Academy of Sciences 98:13925-13930 (2001). DOI: 10.1073/pnas.241320298.

Copies of the research paper are available from the PNAS news office at (202) 334-2138 or by e-mail from pnasnews@nas.edu.

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.